Passar para o conteúdo principal

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Conexão rápida


Dr. Reddy’s Fosaprepitant API offerings

Fosaprepitant is indicated for preventing acute and delayed nausea and vomiting associated with moderately or highly emetogenic chemotherapy combined with other antiemetic agents. The US FDA and EMA approved fosaprepitant in 2008, and the PMDA in 2011. As of December 2020, this corresponds to an API demand of 500 kg per year (IQVIA MAT).

We offer stable amorphous API which meets global regulatory requirements and formulation needs of customers. To know more about Dr. Reddy’s Fosaprepitant offerings Read the technical sheet on this topic by filling the contact form below.

Explore other Whitepapers:

Know More

Download Now

Preencha o formulário de contato abaixo para visualizar o white paper

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting

Active Pharmaceutical Ingredients

API Supplier of the Year

Global Generics & Biosimilars Awards 2021 winner for 3 consecutive years!

Explore our Products